AAAAAA

   
Results: 1-8 |
Results: 8
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
Authors: Rothenberg, ML Kuhn, JG Schaaf, LJ Rodriguez, GI Eckhardt, SG Villalona-Calero, MA Rinaldi, DA Hammond, LA Hodges, S Sharma, A Elfring, GL Petit, RG Locker, PK Miller, LL von Hoff, DD
Citation: Ml. Rothenberg et al., Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks, ANN ONCOL, 12(11), 2001, pp. 1631-1641
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
Authors: Pitot, HC Goldberg, RM Reid, JM Sloan, JA Skaff, PA Erlichman, C Rubin, J Burch, PA Adjei, AA Alberts, SA Schaaf, LJ Elfring, G Miller, LL
Citation: Hc. Pitot et al., Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride(CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy, CLIN CANC R, 6(6), 2000, pp. 2236-2244
The Talbot Collection - National Museum of American History
Authors: Schaaf, LJ
Citation: Lj. Schaaf, The Talbot Collection - National Museum of American History, HIST PHOTOG, 24(1), 2000, pp. 7-15
Leading light
Authors: Schaaf, LJ
Citation: Lj. Schaaf, Leading light, CHEM BRIT, 36(12), 2000, pp. 40-42
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
Authors: DeVore, RF Johnson, DH Crawford, J Garst, J Dimery, IW Eckardt, J Eckhardt, SG Elfring, GL Schaaf, LJ Hanover, CK Miller, LL
Citation: Rf. Devore et al., Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2710-2720
Irinotecan therapy in adults with recurrent or progressive malignant glioma
Authors: Friedman, HS Petros, WP Friedman, AH Schaaf, LJ Kerby, T Lawyer, J Parry, M Houghton, PJ Lovell, S Rasheed, K Cloughsey, T Stewart, ES Colvin, OM Provenzale, JM McLendon, RE Bigner, DD Cokgor, I Haglund, M Rich, J Ashley, D Malczyn, J Elfring, GL Miller, LL
Citation: Hs. Friedman et al., Irinotecan therapy in adults with recurrent or progressive malignant glioma, J CL ONCOL, 17(5), 1999, pp. 1516-1525
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML
Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696
Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors
Authors: Saltz, LB Spriggs, D Schaaf, LJ Schwartz, GK Ilson, D Kemeny, N Kanowitz, J Steger, C Eng, M Albanese, P Semple, D Hanover, CK Elfring, GL Miller, LL Kelsen, D
Citation: Lb. Saltz et al., Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors, J CL ONCOL, 16(12), 1998, pp. 3858-3865
Risultati: 1-8 |